Abivax SA - American Depositary Shares (ABVX)

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Could these two companies be biotech giants in the making?

The choice between the two might come down to each investor's goals and risk tolerance.

And the share price appreciation could happen pretty soon.

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

The stock already looks unstoppable, and this move won't hurt its momentum.

As the final trading days of 2025 wind down, the global investment community has entered a period of intense reflection. This year’s market was defined by a breathtaking "tale of two halves," where record-shattering rallies in semiconductor giants were nearly derailed by a mid-year geopolitical shock that reshaped the

A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality.

Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session.

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results and a staggering 1,400% year-to-date rally, the French biotechnology firm has been officially crowned the most likely acquisition

Investors were excited about the possibility of a buyout with a high price tag.

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?

The financial markets are witnessing a historic "Great Rotation" this December, as the era of defensive posturing and mega-cap concentration appears to be giving way to a broad-based growth rally. Following the Federal Reserve’s third consecutive interest rate cut on December 10, 2025, institutional capital has begun a rapid

These companies are worth your attention.

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.